p16INK4A (CDKN2A) Rabbit Polyclonal Antibody

CAT#: TA301407

Rabbit Polyclonal Antibody against p14ARF

Product Images

Western Blot: p14ARF Antibody TA301407 - Detection of CDKN2A in HeLa whole cell extract.

Specifications

Product Data

• Applications: WB
• Recommended Dilution: Western Blot: 2 ug/ml
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: A synthetic peptide made to a portion of human p14ARF (between residues 100-173). [Swiss-Prot# Q8N726]
• Formulation: Tris-glycine, 150mM NaCl and 0.05% sodium azide
• Concentration: lot specific
• Purification: Affinity purified
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: cyclin-dependent kinase inhibitor 2A
• Database Link:
  NP_000068
  Entrez Gene 1029 Human
  UniProt ID Q8N726
• Background: The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1 alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF.
• Synonyms: ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, p53 signaling pathway, Pancreatic cancer, Pathways in cancer